Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 4/2012

01-08-2012 | The Therapeutic Trials (G Mancia and TD Giles, Section Editors)

Total Cardiovascular Risk, Blood Pressure Variability and Adrenergic Overdrive in Hypertension: Evidence, Mechanisms and Clinical Implications

Authors: Guido Grassi, Michele Bombelli, Gianmaria Brambilla, Fosca Quarti Trevano, Raffaella Dell’Oro, Giuseppe Mancia

Published in: Current Hypertension Reports | Issue 4/2012

Login to get access

Abstract

In hypertensive patients the risk of developing cardiovascular events and complications depends not only on the magnitude of the blood pressure elevation, but also, and to a consistent extent, on the presence of associated cardiovascular risk factors, concomitant disease and target organ damage. Recent findings suggest that also sympathetic overdrive and alterations in blood pressure variability (which are detected in hypertension) may participate at the increased cardiovascular risk of the patients with high blood pressure. This review will discuss the evidence collected over the past few years on the relationships between sympathetic activation and blood pressure variability and their impact on cardiovascular risk profile.
Literature
1.
•• Mancia G, De Backer G, Dominiczak A, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87. The document includes the most recent recommendations on diagnosis and treatment of hypertension made by european experts.PubMedCrossRef
2.
• Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–58. The paper provides a critical upadte of the 2007 guidelines by discussing the evidence collected in importnat clinical trials published between 2007 and 2009.PubMedCrossRef
3.
Mancia G, Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol. 2000;35:S15–9.PubMedCrossRef
4.
• Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690–7. The review provides a comprehensive update of the most recent data collected on the role of the sympathetic nervous sytem in hypertension.PubMedCrossRef
5.
Thomas F, Rudnichi A, Bacri AM, et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension. 2001;37:1256–61.PubMedCrossRef
6.
Bombelli M, Facchetti R, Carugo S, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens. 2009;27:2458–64.PubMedCrossRef
7.
Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21:500–8.PubMedCrossRef
8.
Zanchetti A, Hennig M, Hollweck R, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009;120:1084–90.PubMedCrossRef
9.
Simon A, Megnien JL, Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler Thromb Vasc Biol. 2010;30:182–5.PubMedCrossRef
10.
Cuspidi C, Ambrosioni E, Mancia G, APROS Investigators, et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens. 2002;20:1307–14.PubMedCrossRef
11.
Viazzi F, Parodi D, Leoncini G, et al. Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. J Hypertens. 2004;22:907–13.PubMedCrossRef
12.
Pontremoli R, Ravera M, Bezante GP, et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens. 1999;17:993–1000.PubMedCrossRef
13.
Mancia G, Zanchetti A. Blood pressure variability. In: Zanchetti A, Tarazi R, editors. Handbook of Hypertension. Pathophysiology of hypertension. 7th ed. Amsterdam: Elsevier; 1986. p. 125–52.
14.
Sega R, Cesana G, Bombelli M, et al. Seasonal variations in home and ambulatory blood pressure in the PAMELA population. Pressione Arteriose Monitorate E Loro Associazioni. J Hypertens. 1998;16:1585–92.PubMedCrossRef
15.
Mancia G, Ferrari A, Gregorini L, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res. 1983;53:96–104.PubMedCrossRef
16.
Watson RD, Stallard TJ, Flinn RM, Littler WA. Factors determining direct arterial pressure and its variability in hypertensive man. Hypertension. 1980;2:333–41.PubMedCrossRef
17.
Pickering TG, Hall JE, Appel LJ, et al. Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142–61.PubMed
18.
Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens. 1993;11:1133–7.PubMedCrossRef
19.
Sander D, Kukla C, Klingelhöfer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation. 2000;102:1536–41.PubMedCrossRef
20.
Bird AS, Blizard RA, Mann AH. Treating hypertension in the older person: an evaluation of the association of blood pressure level and its reduction with cognitive performance. J Hypertens. 1990;8:147–52.PubMedCrossRef
21.
Mancia G, Parati G, Hennig M, et al. ELSA Investigators. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2001;19:1981–9.PubMedCrossRef
22.
Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension. 2002;39:710–4.PubMedCrossRef
23.
Kikuya M, Hozawa A, Ohokubo T, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension. 2000;36:901–6.PubMedCrossRef
24.
• Mancia G, Bombelli M, Facchetti R, et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension. 2007;49:1265–70. The study findings provide evidence on the prognostic role exerted by blood pressure variability on fatal and non fatal cardiovascular events.PubMedCrossRef
25.
Pringle E, Phillips C, Thijs L, Syst-Eur investigators, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens. 2003;21:2251–7.PubMedCrossRef
26.
Dawson SL, Manktelow BN, Robinson TG, Panerai RB, Potter JF. Which parameters of beat-to-beat blood pressure and variability best predict early outcome after acute ischemic stroke? Stroke. 2000;31:463–8.PubMedCrossRef
27.
• Kikuya M, Ohkubo T, Metoki H, et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension. 2008;52:1045–50. First demonstration of the potential importance of long-term blood pressure varaibility on cardiovascular events.PubMedCrossRef
28.
• Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160–6. The paper povides bew data on the prognostic importnance of blood pressure variability based on a large data base.PubMedCrossRef
29.
• Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895–905. The study, based on the analysis of the data collected in the Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm [ASCOT-BPLA], provides evidence that visit-to-visit blood pressure variability may be a strong predictor of stroke.PubMedCrossRef
30.
Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375:938–48.PubMedCrossRef
31.
• Mancia G. Prognostic value of long-term blood pressure variability: the evidence is growing. Hypertension. 2011;57:141–3. Critical analysis of the evidence so far obtained on the prognostic role of blood pressure variability.PubMedCrossRef
32.
Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68–72.PubMedCrossRef
33.
Seravalle G, Quarti-Trevano F. Dell’Oro R, et al. Sympathetic, baroreflex and metabolic abnormalities in the optimal, normal and high-normal blood pressure state. J Hypertens. 2010;28:e437.CrossRef
34.
Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38:1711–7.PubMedCrossRef
35.
Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560–5.PubMedCrossRef
36.
Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009;53:205–9.PubMedCrossRef
37.
Grassi G, Seravalle G, Quarti-Trevano F, et al. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension. 2003;42:873–7.PubMedCrossRef
38.
Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846–51.PubMedCrossRef
39.
Grassi G, Dell’Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359–65.PubMedCrossRef
40.
Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:3097–101.PubMedCrossRef
41.
Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–23.PubMedCrossRef
42.
Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354–9.PubMedCrossRef
43.
Rouleau JL, Packer M, Moyé L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol. 1994;24:583–91.PubMedCrossRef
44.
Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology. 2001;57:833–8.PubMedCrossRef
45.
Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-nerve activity during sleep in normal subjects. N Engl J Med. 1993;328:303–7.PubMedCrossRef
46.
Kario K, Pickering TG, Hoshide S, et al. Morning blood pressure surge and hypertensive cerebrovascular disease: role of the α adrenergic sympathetic nervous system. Am J Hypertens. 2004;17:668–75.PubMedCrossRef
47.
Narkiewicz K, Winnicki M, Schroeder K, et al. Relationship between muscle sympathetic nerve activity and diurnal blood pressure profile. Hypertension. 2002;39:168–72.PubMedCrossRef
48.
Grassi G, Seravalle G, Quarti-Trevano F, et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension. 2008;52:925–31.PubMedCrossRef
49.
Grassi G, Cattaneo B, Seravalle G, et al. Baroreflex modulation of minute-to-minute sympathetic nerve traffic variability in normotensive and hypertensive subjects. J Hypertens. 1998;16:S33.
50.
Seravalle G, Dell’Oro R, Vailati S, et al. Baroreflex control of minute-to-minute sympathetic nerve traffic variability in heart failure and in hypertension. Eur Heart K. 1998;19:S144.
51.
Dell’Oro R, Quarti-Trevano F, Facchetti R, et al. Overall, cyclic and non-cyclic 24-hour blood pressure variability and sympathetic nerve traffic in the elderly. J Hypertens. 2003;21:S213.
Metadata
Title
Total Cardiovascular Risk, Blood Pressure Variability and Adrenergic Overdrive in Hypertension: Evidence, Mechanisms and Clinical Implications
Authors
Guido Grassi
Michele Bombelli
Gianmaria Brambilla
Fosca Quarti Trevano
Raffaella Dell’Oro
Giuseppe Mancia
Publication date
01-08-2012
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 4/2012
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-012-0273-8

Other articles of this Issue 4/2012

Current Hypertension Reports 4/2012 Go to the issue

THE Therapeutic Trials (G Mancia and TD Giles, Section Editors)

Oxidative Stress in the Cardiorenal Metabolic Syndrome

Antihypertensive Agents: Mechanisms of Drug Action (HM Siragy and B Waeber, Section Editors)

Vasodilatory Mechanisms of Beta Receptor Blockade

Antihypertensive Agents: Mechanisms of Drug Action (HM Siragy and B Waeber, Section Editors)

Antihypertensive Treatment and Sexual Dysfunction

The Therapeutic Trials (G Mancia and TD Giles, Section Editors)

Recent Clinical Trials in Atrial Fibrillation in Hypertensive Patients

Antihypertensive Agents: Mechanisms of Drug Action (HM Siragy and B Waeber, Section Editors)

Should Two-Drug Initial Therapy for Hypertension Be Recommended for All Patients?

Invited Commentary

Cocoa, Blood Pressure, and Vascular Function
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits